446 The risk of lymphoproliferative disorders and skin cancers in patients with psoriasis and inflammatory bowel disease administered biologics

Few large population-based studies have investigated the effects of biologic agents on risks lymphoproliferative disorders (LPDs) and skin cancers in patients with psoriasis inflammatory bowel disease (IBD). The objective this study are to assess risk LPDs South Korean IBD determine those risks. Health Insurance Review Assessment Service database was reviewed, newly diagnosed or between 2008 2019 were included. exposure biologics cancer assessed using multivariable Cox regression models. Patients at significantly higher for developing Hodgkin lymphoma (HL), non-Hodgkin (NHL), leukemia, nonmelanoma (NMSC), melanoma compared general population. Tumor necrosis factor (TNF)-α inhibitor associated increased overall (adjusted hazard ratio (aHR), 2.93; 95% confidence interval (CI), 1.01–8.50), NHL (aHR, 2.98; CI, 1.02–8.69), cutaneous 3.46; 1.07–11.21) psoriasis. Compared population, Crohn’s ulcerative colitis HL, NHL, NMSC. In patients, 2.47; 1.36–4.47), 2.53; 1.39–4.60), 2.14; 1.02–4.48), leukemia 3.11; 1.45–6.69) by TNF-α inhibitor. conclusion, treatment inhibitors can increase IBD.